Verrica Pharmaceuticals (VRCA) Capital Expenditures (2018 - 2024)
Verrica Pharmaceuticals (VRCA) posted quarterly Capital Expenditures of $16000.0 for Q3 2024, down 75.38% year-over-year from $65000.0 in Q4 2023, and up 45.45% quarter-over-quarter from $11000.0 in Q2 2024.
Verrica Pharmaceuticals (VRCA) Capital Expenditures (2018 - 2024) Analysis & Trends
Verrica Pharmaceuticals' Capital Expenditures history runs 7 years deep, the most recent figure standing at $16000.0 for Q3 2024.
- In Q3 2024, Capital Expenditures fell 75.38% year-over-year to $16000.0; the TTM figure through Dec 2025 stood at $16000.0 (down 40.74% YoY), while the FY2024 annual figure was $27000.0, down 92.54% from the prior year.
- Capital Expenditures for Q3 2024 stood at $16000.0, up from $11000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $699000.0 in Q1 2020, with the low at $5000.0 in Q1 2022.
- The 5-year median for Capital Expenditures is $94000.0 (2020), against an average of $169111.1.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 98.39% in 2022, then surged 243.94% in 2023.
- Verrica Pharmaceuticals' Capital Expenditures stood at $544000.0 in 2020, then tumbled by 56.43% to $237000.0 in 2021, then sank by 72.15% to $66000.0 in 2022, then soared by 243.94% to $227000.0 in 2023, then plunged by 92.95% to $16000.0 in 2024.
- Business Quant data shows VRCA's Capital Expenditures at $16000.0 in Q3 2024, $11000.0 in Q2 2024, and $227000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 11,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 59,000.00 |
| Jun 30, 2023 | 59,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 66,000.00 |
| Dec 31, 2022 | 66,000.00 |
| Sep 30, 2022 | 77,000.00 |
| Sep 30, 2022 | 77,000.00 |
| Jun 30, 2022 | 154,000.00 |
| Jun 30, 2022 | 154,000.00 |
| Mar 31, 2022 | 5,000.00 |
| Mar 31, 2022 | 5,000.00 |